DGIdb - ALENDRONIC ACID Drug Record

ALENDRONIC ACID chembl:CHEMBL870 Approved

Alternate Names:

BINOSTO
ALENDRONIC ACID
ALENDRONATE
FOSAMAX
ACIDO ALENDRONICO
(4-AMINO-1-HYDROXYBUTYLIDENE)BISPHOSPHONIC ACID
FOSAMAX®
G-704650
ACIDUM ALENDRONICUM
BPH 1
ABDP
MK-217
ACIDE ALENDRONIQUE
(4-AMINO-1-HYDROXYBUTANE-1,1-DIYL)BIS(PHOSPHONIC ACID)
4-AMINO-1-HYDROXYBUTANE-1,1-DIPHOSPHONIC ACID
drugbank:00630
rxcui:236083
chemidplus:66376-36-1
chembl:CHEMBL870
rxcui:46041
pubchem.compound:2088

Drug Info:

Drug Class	bisphosphonates
Year of Approval	1995
FDA Approval	1995
Drug Class	small molecule
Drug Indications	Bisphosphonates

(3 More Sources)

Publications:

Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs
Engel et al., 2003, Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture., Calcif. Tissue Int.
Wang C et al., 2015, Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density., Pharmacogenomics J
Palomba et al., 2003, Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes., Clin. Endocrinol. (Oxf)
Mossetti G et al., 2008, Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone., Calcif Tissue Int
Otrock ZK et al., 2008, Vitamin D receptor genotypes and response to zoledronic acid therapy in thalassemia-induced osteoporosis., Ann Hematol
Palomba S et al., 2005, BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial., Osteoporos Int
Tofteng CL et al., 2002, Two polymorphisms in the vitamin D receptor gene--association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study., J Bone Miner Res
Arai H et al., 2001, The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene., J Bone Miner Res
Marc J et al., 1999, VDR genotype and response to etidronate therapy in late postmenopausal women., Osteoporos Int
Yamamoto H et al., 1999, The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine., J Bone Miner Res
Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res
Lambrinoudaki I et al., 2011, BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy., Eur J Neurol
Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer
d'Alésio A et al., 2005, Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls., Hum Mol Genet
International HapMap Consortium., 2003, The International HapMap Project., Nature
Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett
Maffei et al., 2004, Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment., J. Clin. Endocrinol. Metab.

ALENDRONIC ACID MVK

Interaction Score: 15.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25223561

Sources:
PharmGKB
ALENDRONIC ACID PTPN4

Interaction Score: 7.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
ALENDRONIC ACID IL11

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12522661

Sources:
NCI
ALENDRONIC ACID FDPS

Interaction Score: 1.93

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND TTD
ALENDRONIC ACID PTPRC

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15012988

Sources:
DTC
ALENDRONIC ACID PLAU

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11984068

Sources:
NCI
ALENDRONIC ACID CYP19A1

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14715828

Sources:
NCI
ALENDRONIC ACID VDR

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12608943 19020788 18443790 15739035 12162507 11450701 10692979 9933478 21651652 20500803 18470879 16210379 14685227

Sources:
NCI PharmGKB

TEND: ALENDRONATE
- Version: 01-August-2011
Alternate Names:

ALENDRONATE Primary Drug Name

Drug Info:

Year of Approval 1995

Drug Class bisphosphonates

Publications:
TdgClinicalTrial: ALENDRONATE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Bisphosphonates

Drug Class small molecule

FDA Approval 1995

Publications:

NCI: ALENDRONATE

Version: 14-September-2017

Alternate Names:

C973 NCI drug code

Drug Info:

Publications:

Heikkilä et al., 2002, Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines., Anticancer Drugs

Engel et al., 2003, Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture., Calcif. Tissue Int.

Palomba et al., 2003, Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with BsmI vitamin D receptor genotypes., Clin. Endocrinol. (Oxf)

DTC: ALENDRONIC ACID
- Version: 02-September-2020
Alternate Names:

CHEMBL870 ChEMBL Drug ID

Drug Info:

Publications:

Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett

PharmGKB: alendronate

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Hubner RA et al., 2008, Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence., Int J Cancer

Marc J et al., 1999, VDR genotype and response to etidronate therapy in late postmenopausal women., Osteoporos Int

Creatsa M et al., 2011, The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study., J Obstet Gynaecol Res

TTD: Alendronate
- Version: 2020.06.01
Alternate Names:

D09KLR TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL870
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

ALENDRONIC ACID Drug Record

ALENDRONIC ACID chembl:CHEMBL870 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25223561

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12522661

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TEND TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15012988

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11984068

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14715828

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12608943 19020788 18443790 15739035 12162507 11450701 10692979 9933478 21651652 20500803 18470879 16210379 14685227

Sources: NCI PharmGKB

TEND: ALENDRONATE

Alternate Names: ALENDRONATE Primary Drug Name

Drug Info: Year of Approval 1995 Drug Class bisphosphonates

Publications:

TdgClinicalTrial: ALENDRONATE

Alternate Names:

Drug Info: Drug Indications Bisphosphonates Drug Class small molecule FDA Approval 1995

Publications:

NCI: ALENDRONATE

Alternate Names: C973 NCI drug code

Drug Info:

DTC: ALENDRONIC ACID

Alternate Names: CHEMBL870 ChEMBL Drug ID

Drug Info:

Publications: Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett

PharmGKB: alendronate

Alternate Names:

Drug Info:

TTD: Alendronate

Alternate Names: D09KLR TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL870

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
25223561

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TEND

Interaction Types & Directionality:

n/a

PMIDs:
12522661

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND TTD

Interaction Types & Directionality:

n/a

PMIDs:
15012988

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
11984068

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14715828

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12608943 19020788 18443790 15739035 12162507 11450701 10692979 9933478 21651652 20500803 18470879 16210379 14685227

Sources:
NCI PharmGKB

Alternate Names:

ALENDRONATE Primary Drug Name

Drug Info:

Year of Approval 1995

Drug Class bisphosphonates

Drug Info:

Drug Indications Bisphosphonates

Drug Class small molecule

FDA Approval 1995

Alternate Names:

C973 NCI drug code

Alternate Names:

CHEMBL870 ChEMBL Drug ID

Publications:

Tjernberg A et al., 2004, Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)., Bioorg Med Chem Lett

Alternate Names:

D09KLR TTD Drug ID